teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12...20212223242526272829303132»
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Enrollment change:  Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries (clinicaltrials.gov) -  Jun 14, 2019   
    P=N/A,  N=72600, Active, not recruiting, 
    Finally, pharmacological inhibition of PIM proteins not only diminished PC cell proliferation, but also small-molecule pan-PIM and PIM-3 inhibitors synergized with Gem in growth inhibition of PC cells. N=34600 --> 72600
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen
    Journal:  Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. (Pubmed Central) -  May 25, 2019   
    Some of those processes can be targeted using medications with immunomodulatory and neuroprotective properties such as dimethyl fumarate, teriflunomide, or minocycline. In this review, we will summarize the knowledge about key pathogenic processes involved in HAND and potential therapeutic avenues to target HAND.
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  AUBACOG: Cognition and MRI Markers in MS Patients With Aubagio (clinicaltrials.gov) -  May 22, 2019   
    P=N/A,  N=80, Recruiting, 
    In this review, we will summarize the knowledge about key pathogenic processes involved in HAND and potential therapeutic avenues to target HAND. Not yet recruiting --> Recruiting | Trial completion date: Jan 2019 --> May 2022 | Initiation date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2019 --> May 2022
  • ||||||||||  teriflunomide / Generic mfg., cyclophosphamide / Generic mfg.
    Trial completion date, Trial primary completion date:  Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=110, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Sep 2024 | Trial primary completion date: Feb 2018 --> Sep 2023
  • ||||||||||  doxorubicin hydrochloride / generics
    Journal:  Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin. (Pubmed Central) -  Apr 19, 2019   
    Cell cycle regulatory proteins, cyclin B and its binding partner pcdc-2 and p21 were significantly downregulated and upregulated respectively following the combined treatment. Given that we have observed synergistic effects with BQR and doxorubicin, both in vitro and in vivo, these drugs potentially represent a new combination in the targeted therapy of melanoma.
  • ||||||||||  tacrolimus / generics
    FDA event, Review, Journal:  An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis. (Pubmed Central) -  Apr 13, 2019   
    As proof-of-concept, we also tested drug treatment of disease-relevant mammalian cells. While leflunomide treatment inhibited the viability of several human NCSC-derived neuroblastoma cell lines coincident with altered expression of genes involved in ribosome biogenesis and transcription, FK506 enhanced murine calvarial osteoblast differentiation and prevented fusion of the coronal suture in calvarial explants taken from Crouzon syndrome mice.
  • ||||||||||  teriflunomide / generics
    Journal, PD(L)-1 Biomarker, IO Biomarker:  Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations. (Pubmed Central) -  Apr 12, 2019   
    While leflunomide treatment inhibited the viability of several human NCSC-derived neuroblastoma cell lines coincident with altered expression of genes involved in ribosome biogenesis and transcription, FK506 enhanced murine calvarial osteoblast differentiation and prevented fusion of the coronal suture in calvarial explants taken from Crouzon syndrome mice. We identify teriflunomide as a possible medication not only for PMS but also for inflammation-related genetic diseases of the nervous system for which causal treatment options are presently lacking.
  • ||||||||||  teriflunomide / generics
    Journal:  Teriflunomide promotes oligodendroglial differentiation and myelination. (Pubmed Central) -  Apr 7, 2019   
    Results should be interpreted with caution as head-to-head comparisons are not available. Our findings indicate a critical window of opportunity during which regenerative oligodendroglial activities including myelination of CNS axons can be stimulated by teriflunomide.
  • ||||||||||  teriflunomide / generics
    Journal:  Palmar pustular psoriasis associated with teriflunomide treatment. (Pubmed Central) -  Apr 7, 2019   
    Predictors of persistence or adherence with immediate practical application were lacking; this highlights the challenges in optimizing drug therapy. Pustular psoriasis can be triggered by medications but has not been previously reported in association with teriflunomide treatment, to the best of our knowledge.
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) -  Apr 4, 2019   
    P4,  N=193, Recruiting, 
    Immunoprophylaxis and some chemoprophylaxis reduce the infectious risk and allow a more confident use of the chosen DMT. Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022
  • ||||||||||  teriflunomide / generics, leflunomide / generics
    Journal:  Antiviral activity of A771726, the active metabolite of leflunomide, against Junín virus. (Pubmed Central) -  Apr 3, 2019   
    In conclusion, these results suggest that the antiviral target would be viral RNA synthesis through pyrimidine depletion, but any other effect of the compound on JUNV infection cannot be excluded. This study opens the possibility of the therapeutic application of a wide spectrum host-targeted compound alone or in combination with ribavirin to combat AHF as well as other human pathogenic arenaviruses.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Enrollment open, Trial initiation date, Trial primary completion date:  DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) -  Jan 31, 2019   
    P4,  N=800, Recruiting, 
    This study opens the possibility of the therapeutic application of a wide spectrum host-targeted compound alone or in combination with ribavirin to combat AHF as well as other human pathogenic arenaviruses. Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Teriflunomide Male Transmission Study (clinicaltrials.gov) -  Jan 2, 2019   
    P=N/A,  N=20, Completed, 
    Initiation date: Sep 2018 --> Sep 2017 Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Oct 2017 --> Aug 2018
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion date, Trial primary completion date:  Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis (clinicaltrials.gov) -  Nov 15, 2018   
    P=N/A,  N=60, Recruiting, 
    Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Oct 2017 --> Aug 2018 Trial completion date: Aug 2019 --> Nov 2020 | Trial primary completion date: Aug 2018 --> Nov 2020
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Enrollment closed:  Teriflunomide Tecfidera LMCE (clinicaltrials.gov) -  Oct 15, 2018   
    P=N/A,  N=120, Active, not recruiting, 
    Initiation date: Sep 2017 --> Sep 2018 Not yet recruiting --> Active, not recruiting
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    New trial:  Teriflunomide Tecfidera LMCE (clinicaltrials.gov) -  May 18, 2018   
    P=N/A,  N=120, Not yet recruiting, 
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment open:  Mechanistic Studies of Teriflunomide in RRMS (clinicaltrials.gov) -  Apr 20, 2018   
    P=N/A,  N=30, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting